Free tool
FAERS Monitor: Valtrex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020487 or its brand name (Valtrex, Valacyclovir Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
46,257
Serious
33,410
72% of reports
Hospitalization
18,492
Death reported
3,756
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,802
- nausea2,783
- fatigue2,678
- off label use2,480
- diarrhoea2,261
- headache2,071
- pyrexia2,056
- pain1,833
- dizziness1,622
- vomiting1,562
- pneumonia1,516
- rash1,458
- dyspnoea1,446
- asthenia1,337
- acute kidney injury1,216
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 708 |
| 2005 | 798 |
| 2006 | 898 |
| 2007 | 1,057 |
| 2008 | 1,190 |
| 2009 | 1,149 |
| 2010 | 1,173 |
| 2011 | 1,241 |
| 2012 | 1,500 |
| 2013 | 1,127 |
| 2014 | 1,205 |
| 2015 | 1,893 |
| 2016 | 2,107 |
| 2017 | 1,692 |
| 2018 | 1,881 |
| 2019 | 2,199 |
| 2020 | 2,361 |
| 2021 | 2,984 |
| 2022 | 4,618 |
| 2023 | 4,268 |
| 2024 | 4,135 |
| 2025 | 3,689 |
| 2026 | 2,382 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,902 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,216 | 3.6 | 3.4 | 2,317 |
| pyrexiaSignal | 2,056 | 2.7 | 2.6 | 2,244 |
| pneumoniaSignal | 1,516 | 2.1 | 2.0 | 923 |
| asthenia | 1,337 | 1.6 | 1.5 | 320 |
| nausea | 2,783 | 1.6 | 1.5 | 649 |
| diarrhoea | 2,261 | 1.6 | 1.5 | 515 |
| fatigue | 2,678 | 1.6 | 1.5 | 566 |
| rash | 1,458 | 1.5 | 1.4 | 266 |
| vomiting | 1,562 | 1.5 | 1.4 | 276 |
| headache | 2,071 | 1.5 | 1.4 | 358 |
| dizziness | 1,622 | 1.5 | 1.4 | 258 |
| pain | 1,833 | 1.4 | 1.3 | 177 |
| off label use | 2,480 | 1.3 | 1.2 | 167 |
| dyspnoea | 1,446 | 1.2 | 1.1 | 33 |
| drug ineffective | 2,802 | 1.0 | 0.9 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.